Immunogenicity and Protection from a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis

Anna Lena Lopez, Jacqueline Deen, Andrew S. Azman, Francisco J. Luquero, Suman Kanungo, Shanta Dutta, Lorenz Von Seidlein, David A. Sack

Research output: Contribution to journalReview article


In addition to improved water supply and sanitation, the 2-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efcacy and effectiveness) conferred by a single OCV dose against cholera. Te metaanalysis showed that an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, afer an OCV frst dose. Te estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufcient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggest otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.

Original languageEnglish (US)
Pages (from-to)1960-1971
Number of pages12
JournalClinical Infectious Diseases
Issue number12
StatePublished - Jun 1 2018



  • Vibrio cholera
  • cholera
  • cholera vaccine
  • oral cholera vaccine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this